Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity

Leukemia Research

Volumn 29, Issue 11, 2005, Pages 1253-1257

  Flinn, Ian W ^a   Byrd, John C ^b   Bartlett, Nancy ^c   Kipps, Thomas ^d   Gribben, John ^e   Thomas, Deborah ^f   Larson, Richard A ^g   Rai, Kanti ^h   Petric, Rosemary ⁱ   Ramon Suerez, Jose ⁱ   Gabrilove, Janice ^j   Grever, Michael R ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF CHICAGO   (United States)

^h LONG ISLAND JEWISH MEDICAL CENTER   (United States)

ⁱ SANOFI   (France)

^j MOUNT SINAI HOSPITAL   (United States)

more..

Author keywords

CLL; Flavopiridol; Fludarabine refractory

Indexed keywords

ACICLOVIR; ALLOPURINOL; COLESTIPOL; COTRIMOXAZOLE; FLAVOPIRIDOL; LOPERAMIDE;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PAIN; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DOSE RESPONSE; DRUG ACTIVITY; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEART VENTRICLE ARRHYTHMIA; HEMOLYTIC ANEMIA; HUMAN; HYPERCALCEMIA; HYPERGLYCEMIA; HYPERKALEMIA; ILEUS; INFECTION; MALE; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SYMPTOM; SYNCOPE; THROMBOCYTOPENIA; THROMBUS;

ADULT; AGED; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLAVONOIDS; HUMANS; INFUSIONS, INTRAVENOUS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MALE; MIDDLE AGED; PIPERIDINES; TIME FACTORS; TREATMENT OUTCOME;

EID: 20344382459     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2005.03.010     Document Type: Article

References (31)

1. S. Johnson, A.G. Smith, H. Loffler The French Cooperative Group on CLL Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia Lancet 347 1996 1432 1438
2. M. Leporrier, S. Chevret, and B. Cazin Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients Blood 98 2001 2319 2325
3. K.R. Rai, B.L. Peterson, and F.R. Appelbaum Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukaemia N Engl J Med 343 2000 1750 1757
4. S.M. O'Brien, H.M. Kantarjian, and J. Cortes Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukaemia J Clin Oncol 19 2001 1414 1420
5. I.W. Flinn, J.C. Byrd, and C. Morrison Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies Blood 96 2000 71 75
6. J.C. Byrd, B.L. Peterson, and V.A. Morrison Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 CALGB 9712 Blood 101 2003 6 14
7. M.J.M.T. Keating, S. O'Brien, W. Wierda, H. Kantarjian, S. Lerner, and M. Albitar A high proportion of true complete remission can be obtained with a fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia Proc Am Soc Clin Oncol:abstr 2289 2003
8. H. Schulz, S.K. Klein, and U. Rehwald Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukaemia Blood 100 2002 3115 3120
9. B.A. Carlson, M.M. Dubay, and E.A. Sausville Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells Cancer Res 1996
10. G. Kaur, M. Stetler-Stevenson, and S. Sebers Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275 J Natl Cancer Inst 1992 1736 1740
11. E.A. Sausville, J. Johnson, and M. Alley Inhibition of CDKs as a therapeutic modality Ann N Y Acad Sci 2000 207 222
12. A.M. Senderowicz, and Sausville EA Preclinical and clinical development of cyclin-dependent kinase modulators J Natl Cancer Inst 2000 376 387
13. S. Kitada, J.M. Zapata, and M. Andreeff Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia Blood 2000 393 397
14. J.C. Byrd, C. Shinn, and J.K. Waselenko Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 Blood 1998 3804 3816
15. A. Konig, G.K. Schwartz, and R.M. Mohammad The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines Blood 1997 4307 4312
16. B.W. Parker, G. Kaur, and W. Nieves-Neira Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol Blood 1998 458 465
17. A. Konig, G.K. Schwartz, and R.M. Mohammad The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines Blood 90 1997 4307 4312
18. S. Kitada, J.M. Zapata, and M. Andreeff Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukaemia Blood 96 2000 393 397
19. J.C. Byrd, C. Shinn, and J.K. Waselenko Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53 Blood 92 1998 3804 3816
20. C. Pepper, A. Thomas, and T. Hoy Leukemic and non-leukemic lymphocytes from patients with Li Fraumeni syndrome demonstrate loss of p53 function Bcl-2 family dysregulation and intrinsic resistance to conventional chemotherapeutic drugs but not flavopiridol Cell Cycle 2 2003 53 58
21. B.D. Cheson, J.M. Bennett, and M. Grever National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment Blood 87 1996 4990 4997
22. Byrd JC, Peterson BL, Gabrilove J, et al. Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus flavopiridol: results from Cancer and Leukemia Group B study 19805. Clin Cancer Res 2005;in press.
23. J.P. Thomas, K.D. Tutsch, and J.F. Cleary Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol Cancer Chemother Pharmacol 50 2002 465 472
24. A.M. Senderowicz, D. Headlee, and S.F. Stinson Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms J Clin Oncol 16 1998 2986 2999
25. M.A. Rudek, K.S. Bauer Jr., and R.M. Lush 3rd Clinical pharmacology of flavopiridol following a 72-hour continuous infusion Ann Pharmacother 37 2003 1369 1374
26. G.I. Shapiro, J.G. Supko, and A. Patterson A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer Clin Cancer Res 7 2001 1590 1599
27. C. Shinn, D. Larsen, and J.R. Suarez Flavopiridol sensitivity of chronic lymphocytic leukemia (CLL) cells in vitro varies based upon species specific drug protein binding Blood 2000 294b
28. F. Innocenti, W.M. Stadler, and L. Iyer Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea Clin Cancer Res 2000 3400 3405
29. G.I. Shapiro, J.G. Supko, and A. Patterson A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer Clin Cancer Res 2001 1590 1599
30. A.R. Tan, D. Headlee, and R. Messmann Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms J Clin Oncol 20 2002 4074 4082
31. JC. Byrd, T. Lin, and J. Dalton Flavopiridol administered as a pharmacologically derived schedule demonstrates marked clinical activity in refractory, genetically high risk chronic lymphocytic leukemia Blood 104 2004 101a [abstract]